Beyond Borders: ImmunoACT and India's Emergence as one of the World's Most Accessible CAR-T Destination
Apr 29, 2026
New Delhi [India], April 29: A patient from Mauritius with relapsed aggressive non-Hodgkin's lymphoma travelled to India for an indigenously manufactured CAR-T cell therapy by ImmunoACT, a treatment that would have cost millions of dollars in the United States. His story is part of a quiet but growing trend: ImmunoACT has now treated close to 60 patients from 20+ countries across five continents positioning India as an emerging destination for accessible CAR-T therapy [based on data collected from company and treatment centres].
Read More...
